Purpose: Pooled evaluation of the key efficacy and safety profile of eslicarbazepine acetate (ESL) added-on to stable antiepileptic therapy in adults with focal-onset seizures.
| INTRODUCTION
Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug (AED) that has been approved by the European Medicines Agency (EMA), (NCT00957684), -302 (NCT00957047), -303 (NCT00957372), and -304 (NCT00988429). All studies followed a similar design with ESL administered at once-daily doses for 12 weeks (maintenance period).
The only major differences in study designs were the number of ESL doses tested and the titration and tapering-off regimens ( Figure 1 ).
Studies BIA-2093-301 and −302 had three ESL dose groups (400 mg, 800 mg or 1200 mg once-daily), while study −303 and −304 had only two (800 mg or 1200 mg once-daily). The main results of each individual study have been published elsewhere. [1] [2] [3] [4] To better understand the efficacy and safety profile of ESL in a broader population and to perform additional analyses in patient subpopulations, data from the four studies were pooled and analyzed.
The results of this integrated analysis, which had been planned in the study protocols, and are reported here, had three key variables to assess efficacy over the 12-week maintenance period: (i) standardized seizure frequency (the primary efficacy variable), (ii) relative change in seizure frequency, and (iii) the responder rate (≥50% reduction in seizure frequency). However, as major protocol violations raised doubts on the reliability of the study results in Study BIA-2093-303 (included in the supplementary information), 5 the main results of the present combined analysis are displayed with and without Study −303. In fact, Study −303 was endowed with a difference between intention-to- AEs leading to discontinuation was dose dependent. Most common AEs (>10% patients) were dizziness, somnolence, and nausea. The incidence of treatment-emergent AEs (dizziness, somnolence, ataxia, vomiting, and nausea) was lower in patients who began taking ESL 400 mg (followed by 400 mg increments to 800 or 1200 mg) than in those who began taking ESL 600 mg or 800 mg.
Conclusions:
Once-daily ESL 800 mg and 1200 mg showed consistent results across all efficacy and safety endpoints, independent of study population characteristics and type of concomitant AEDs. Treatment initiated with ESL 400 mg followed by 400 mg increments to 800 or 1200 mg provides optimal balance of efficacy and tolerability.
K E Y W O R D S
adjunctive therapy, adults, antiepileptic drugs, eslicarbazepine acetate, focal-onset seizures, refractory epilepsy F I G U R E 1 Study design adjunctive ESL trial to include North American patients, and data from this trial were not part of the Gil-Nagel et al's pooled analysis.
6 Also, the current pooled analysis allows the assessment of detailed safety data by titration regimen and efficacy by other subgroups. In study 304, event diaries and daily diaries were used. If the diary was returned and there was no seizure information available for a particular day, it was assumed as missing seizure data and the day was then excluded from the calculation of the primary endpoint.
| PATIENTS AND METHODS
The studies were approved by the appropriate independent ethics committees or institutional review boards and were conducted according to the international and local regulations of the countries where they were performed. Patients gave their written informed consent prior to enrolment. Main baseline population characteristics are presented in Table   S1 . The population in the four studies was predominantly Caucasian (Table S2 ). All patients but five were taking at least one concomitant AED at the end of the baseline period (majority were under two AEDs in parallel, Table S3 ). The most common AEDs being taken at the end of the baseline period were CBZ (>48% in any group), lamotrigine (LTG) (>20% in any group), and valproic acid (VPA) (>18% in any group). Table S3 lists concomitant AEDs taken by more than 3% of patients in any treatment group. During the baseline period of the studies, AEDs were discontinued only for 2.0% of patients on placebo, 2.1% of patients on ESL 400 mg, 2.6% of patients on ESL 800 mg, and 2.1% of patients on ESL 1200 mg.
| RESULTS

| Analysis of populations
| Efficacy Results
The median SSF at baseline (Table 1) partial: 7.0) ( Table 1 ). The ANCOVA of SSF is presented in Table S4 .
Compared to the placebo group the change in SSF during the maintenance period was statistically significant for the ESL 800 mg and 1200 mg groups in the ITT and PP populations ( Figure 2A for full and Figure 2B for partial integrated analysis; see also Table S4 ). In the full ITT integrated ANCOVA analysis, the least square (LS) mean SSF was lowest in the ESL 1200 mg group (6.11) and highest in the placebo group (7.95). In the partial ITT integrated analysis, the LS mean SSF was also lowest in the ESL 1200 mg group (6.35) and highest in the placebo group (8.27) ( Figure 2A for full and Figure 2B for partial integrated analysis; see also Table S4 ).
The LS means and 95% confidence intervals (CI) of relative reduction in SSF over the 12-week maintenance period are displayed in
Figures 2C and D for full and partial integrated analysis, respectively.
The relative reduction in SSF during the maintenance period was significantly higher (P < 0.0001) for the ESL 800 mg and 1200 mg groups compared to the placebo group in both the ITT and PP populations (Figures 2C and D for full and partial integrated analysis, respectively).
In the full integrated analysis, the median relative change was −17.6%
in the placebo group compared to −23.4% in the ESL 400 mg group, −33.4% in the ESL 800 mg group, and −37.8% in the ESL 1200 mg group ( Figure 2C ). In the partial integrated ANCOVA analysis, the change of LS mean was also greatest in the ESL 1200 mg group (−36.6) and lowest in the placebo group (−17.3) ( Figure 2D ).
Figures 2E and F presents the percentage of responders (patients with a≥50% decrease in SSF relative to baseline). The responder rate was significantly higher in the ESL 800 mg and 1200 mg groups than in the placebo group in each of the 4 studies as well as either in the full or partial integrated analyses. In either full or partial integrated analyses, the difference to placebo was statistically significant (P ≤ 0.0001)
for the ESL 800 mg and 1200 mg groups; the difference between the ESL 400 mg group and placebo was not statistically significant. The responder rate for ESL 400 mg was 22.9% for full and for partial integrated analyses, for ESL 800 mg was 33.8% for full and 33.2% for partial integrated analyses, and for ESL 1200 mg 43.1% and 43.0%, respectively (placebo: 22.2% and 21.2%).
In the full integrated analysis, a larger proportion of patients had a reduction in SSF of 25% or more in the ESL 800 mg (58.3%) and ESL 1200 mg group (60.4%) compared to placebo patients (43.0%).
An exacerbation of seizure frequency was observed in less than 24% of patients for any ESL group, but in 33.4% of placebo patients ( Figure 2G ). In the partial integrated analysis, a larger proportion of patients had a reduction in SSF of 25% or more in the ESL 800 mg (57.1%) and ESL 1200 mg group (60.5%) compared to placebo patients (41.9%), while less than 24% of patients in any ESL group had an exacerbation of SSF compared to 33.0% of placebo patients ( Figure 2H ).
Analyses performed to demonstrate the robustness of the findings for SSF were consistent with the results shown above for Model I without treatment-by-study interaction. There was no indication that the treatment effect was different across studies.
The ANCOVA of SSF by seizure type showed a difference compared to placebo that was statistically significant at ESL 800 mg (P = 0.0096) for simple partial seizures, at both ESL 800 mg (P = 0.0108) and 1200 mg (P < 0.0001) for complex partial seizures, and at ESL 1200 mg (P = 0.0101) for partial seizures evolving to secondarily generalized ( Figure S1 ). A dose-dependent and statistically significant difference for both ESL 800 mg and 1200 mg compared to placebo for simple partial and complex partial seizures was observed in the previous pooled analysis conducted with studies 301, 302, and 303. The inclusion of study 304 data appears to have an impact for this particular analysis. Although the influence of geographic region on treatment response was found not to be statistically significant (P = 0.38), in the North American subgroup, there was no statistically significant difference in seizure frequency between the both 800 and ESL 1200 mg and placebo. In the rest of the world subgroup, seizure frequency was significantly lower in both the 800 mg and ESL 1200 mg than the placebo group [5] .
In the full pooled ITT population, at baseline the mean±SD (median) number of days with seizures per 4 weeks was 8.7 ± 6.1 (6.2) for placebo, 8.5 ± 5.6 (6.5) for the ESL 400 mg group, 8.9 ± 6.3 (6.6) for ESL 800 mg and 8.9 ± 6.3 (6.5) for ESL 1200 mg. During the maintenance period, the mean±SD (median) number of days with seizures per 4 weeks, during the maintenance period, decreased to 7.3 ± 6.2 (5.3) for placebo, 7.0 ± 5.8 (5.1) for ESL 400 mg, 6.5 ± 6.3 (4.3) for ESL 800 mg and 6.5 ± 6.4 (4.2) for ESL 1200 mg. The decrease in the number of days with seizures was statistically significant in the ESL 800 mg once-daily (P = 0.0005) and ESL 1200 mg once-daily (P = 0.0001) groups, when compared to placebo. During the maintenance period, the proportion of patients who were seizure-free increased with increasing dose of ESL, from 2.0% for the ESL 400 mg group, 3.7% for the ESL 800 mg group to 5.7% for the ESL 1200 mg group, compared to 2.0% for placebo.
Regardless of whichever concomitant baseline AEDs were used, efficacy of ESL 800 mg and 1200 mg was demonstrated during the maintenance period. For either the full or partial pooled data, median relative reduction in SSF by ESL was similar in patients taking CBZ or not ( Figure S2 ). The median relative reduction in SSF was almost identical between patients taking and not taking LTG ( Figure   S2 ), and between patients taking or not taking VPA ( Figure S2 ).
These results are consistent with those reported for the responder rates. ITT, intention-to-treat; N, total number of subjects; SD, standard deviation; ESL, eslicarbazepine acetate.
T (Table S1 ). Therefore, it was not possible to make meaningful comparisons between ESL and placebo for elderly patients.
The efficacy observed in each dose group was generally comparable for patients taking 1 AED and those taking 2 AEDs. A meaningful comparison to patients who took >2 AEDs (N = 51) or did not take any AEDs (N = 3) was not possible due to the small number of patients in this sub-population. In the pooled data from ITT population of 4 studies, the median relative reduction in SSF was similar in patients tak- 
| Safety results
| Adverse events
In the full integrated analysis, the overall incidence of treatmentemergent AEs (TEAEs) increased with increasing doses of ESL, both for all TEAEs as well as for those considered possibly related (Table 2) , which was similar to that observed in the partial integrated analysis. This was also observed for TEAEs leading to study discontinuation (mainly dizziness and nausea). Hyponatremia leading to treatment discontinuation occurred in less than 1% of patients taking ESL. No dose-dependent trend was observed for serious TEAEs The incidence of TEAEs reported by at least 10% of patients in any treatment group (dizziness, somnolence headache, and nausea) is depicted in Table 2 . The majority of TEAEs were mild or moderate in severity. The difference in the frequency of TEAEs between the ESL and the placebo groups was observed mainly during the first 6 weeks of treatment. Thereafter, the frequency of TEAEs reported in the ESL and the placebo groups was similar.
The incidence of TEAEs in the pooled data from the full safety population was higher in women (73%) treated with ESL than in men (64.6%), which was comparable to the incidence in placebo treated patients (women 56.7%; men 49%). The difference in ESL group was accounted for mainly by the difference in the ESL 1200 mg group (women 79.1%; men 66.5%). Figure 3 illustrates the incidence of TEAEs in both full and partial pooled safety data during the double-blind period. The incidence of TEAEs, namely dizziness, somnolence, ataxia, vomiting, and nausea, was lower in patients who started with taking ESL 400 mg (followed by 400 mg increments to ESL 800 mg or 1200 mg) than in those who started on ESL 600 mg or 800 mg, regardless of dosing schedule or eventual maintenance dose.
| Clinical laboratory assessments
No clinically relevant findings were found to be associated with changes in mean clinical laboratory parameters (hematology, blood chemistry, urine, and coagulation). An incidence of clinically significant hematologic abnormalities of less than 4% in any treatment group was In at least 1% of patients in any treatment group. c In at least 5% of patients in any treatment group. patients treated with placebo, and in 6.1%, 4.8%, and 6.6% of patients treated with ESL 400 mg, 800 mg, and 1200 mg, respectively. A shift from normal at baseline to high (>146 mEq/L) at the end of the maintenance period was reported in 1.1%, 0.0%, 1.4%, and 0.3% of patients treated with ESL 400 mg, 800 mg, and 1200 mg, respectively. Hyponatremia <125 mEq/L was reported in 17 patients: 1 (0.5%) on ESL 400 mg, 6 (1.2%) on 800 mg, and 10 (2.0%) on 1200 mg. The increase and decrease in LDL-cholesterol from normal at baseline to high or low at the end of the maintenance treatment period were comparable between the ESL groups and the placebo group. For HDL-cholesterol, the increase from normal at baseline to high at the end of the maintenance treatment period was dose dependent in the ESL groups and higher than in the placebo group; no trend was observed for decreases from normal at baseline to low at the end of the maintenance treatment period. No changes in vital signs or body weight were of clinical concern.
| DISCUSSION
The pooling of data from multiple studies with similar designs and similar patient populations can be a powerful tool to address clinical questions not readily answered in the individual studies.
7 Therefore, a combined analysis of the pivotal studies of ESL as adjunctive therapy in adults with FOS with or without secondary generalization was planned in the study protocols.
This integrated analysis demonstrated that adjunctive therapy with 800 mg and 1200 mg ESL once-daily doses was efficacious and well tolerated in treatment of patients with partial-onset seizures refractory to stable AED treatment. The efficacy of ESL 800 mg and 1200 mg once-daily doses clearly showed consistent results across all efficacy endpoints and was independent of study population characteristics as well as the type and number of concomitant AEDs used. SSF was significantly reduced with ESL 800 mg oncedaily (P < 0.0001) and 1200 mg once-daily (P < 0.0001) compared to placebo.
The integrated analysis did not identify any patient characteristic that would predict a decrease or increase in ESL efficacy. ESL 800 mg and 1200 mg were more efficacious than placebo regardless of gen- . [25] [26] [27] Despite the lack of head-to-head efficacy trials between ESL and OXC in patients with epilepsy, the overall incidence of discontinuations due to TEAEs was 4.5% for placebo, 8.7% for ESL 400 mg, 11.6% for ESL 800 mg, and 19.3% for ESL 1200 mg once daily in phase III studies, 1-3 whereas incidence of discontinuations for OXC in a large study with similar design was 8.7% for placebo and ranged from 11.9%-36.2% on similar doses of twice-daily 300 and 600 mg, respectively. 28 In comparison with OXC, administration of ESL resulted in more eslicarbazepine, less R-licarbazepine, and less oxcarbazepine in plasma and cerebrospinal fluid (CSF) of healthy volunteers, which may correlate with the tolerability profile reported with ESL. 29 The smaller peak-to-trough fluctuation of eslicarbazepine in CSF (a measure of sustained delivery to the brain) than in plasma supports once-daily dosing of ESL. 29 In addition, comparison to twice-daily OXC administration of once-daily ESL resulted in 40.6% increase of plasma eslicarbazepine in association with less (R)-licarbazepine and oxcarbazepine plasma levels, which may correlate with the therapeutic profile reported with ESL.
30
Although a better tolerability profile has been reported with slow release vs immediate release formulations of OXC, 31 it is unknown whether this is related to differences in exposure to oxcarbazepine and its metabolites.
A higher incidence of diplopia, nausea, abnormal coordination, dizziness, headache, and somnolence in the 800 mg and ESL 1200 mg groups was the primary reason for the observed dosedependent increase in the frequency of TEAEs. The difference in the frequency of TEAEs between the ESL treatment groups and the placebo group was observed mainly during the first weeks of treatment. Patients who started titration at a higher dose of ESL showed a higher incidence of TEAEs. Discontinuation due to TEAEs was dose-dependent, ranging from 6% in the placebo group to 22% in the ESL 1200 mg group in the pooled data from safety population of four studies. Hyponatremia leading to treatment discontinuation occurred in less than 1% of patients taking ESL. The total discontinuation rate for ESL patients was 14%, which is low compared to rates reported in a study with OXC 28, 32 where incidences of discontinuation of 12%, 36%, and 67% were found following OXC daily doses of, respectively, 600 mg, 1200 mg, and 2400 mg, and similar to rates reported for other AEDs, such as LTG, topiramate, and tiagabine. 33 On the other hand, open studies have also demonstrated improvements in tolerability in patients switched overnight from OXC to ESL. 34, 35 Due to differences in pharmacokinetics, pharmacodynamics, and metabolism, there may be clinical situations in which it is appropriate to consider switching patients from OXC or CBZ to ESL. 36 In line with the findings from Zaccara et al, for which ESL was significantly associated with a lower withdrawal rate due to AEs than OXC. 32 Changes in mean clinical laboratory parameters (hematology, blood chemistry, urine, and coagulation) did not reveal clinically relevant findings. None of the hematology parameters showed a dose dependency. Very few patients had clinically significant abnormalities in biochemistry parameters (<1.8% in any treatment group) or liver function tests (<1% in any treatment group). Hyponatremia <125 mEq/L was reported in ≤ 2% of patients taking ESL. Changes in HDL-and LDL-cholesterol were comparable between the ESL groups and the placebo group; however, for HDL-cholesterol, the increase from normal at baseline to high at the end of the maintenance treatment period was dose-dependent in the ESL groups and higher than in the placebo group.
In conclusion, once-daily ESL 800 mg and 1200 mg showed consistent results across all efficacy and safety endpoints, independent of study population characteristics and type of concomitant AEDs.
Treatment initiated with ESL 400 mg followed by 400 mg increments to 800 or 1200 mg provides optimal balance of efficacy and tolerability.
